Carcinoid Syndrome Clinical Trial
Official title:
Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET
This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11 alpha-methyltryptophan (AMT)-emission tomography (PET). Telotristat etiprate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying the changes within the tumor cells via AMT-PET may help doctors better understand how tumors respond to treatment with telotristat etiprate.
PRIMARY OBJECTIVES: I. To evaluate the effect of telotristat etiprate (telotristat ethyl) treatment in patients with advanced neuroendocrine tumors (NETs) using carbon C 11 alpha-methyltryptophan (alpha-[11C]methyl-?L-?tryptophan) (AMT)-?positron emission tomography (PET) as measured by changes in tumor maximum standardized uptake value (SUVmax). SECONDARY OBJECTIVES: I. Show that NETs will have increased AMT uptake on PET, as compared to surrounding non-tumor tissue at baseline. II. Use compartmental modeling (in tumors with the left ventricle of the heart in the field-of-view) to measure change in AMT retention. III. Measure change in AMT retention as mean standardized uptake value (SUVmean). OUTLINE: Participants undergo AMT-PET within 7 days prior to, and 9-14 days after start of telotristat etiprate treatment. Participants receive telotristat etiprate orally (PO) three times a day (TID) for 9-14 days. After completion of study treatment, participants are followed up for 3 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04993261 -
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
|
Early Phase 1 | |
| Not yet recruiting |
NCT04039516 -
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
|
Phase 2 | |
| Completed |
NCT01234168 -
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
|
||
| Terminated |
NCT04073017 -
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
|
N/A | |
| Recruiting |
NCT05756608 -
Fibrosis in Chronic and Delayed Myocardial Infarction
|
||
| Completed |
NCT00774930 -
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
|
Phase 3 | |
| Withdrawn |
NCT04713202 -
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
|
Phase 2 | |
| Completed |
NCT00853047 -
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
|
Phase 2 | |
| Completed |
NCT02063659 -
Telotristat Etiprate for Carcinoid Syndrome Therapy
|
Phase 3 | |
| Withdrawn |
NCT04776876 -
Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
|
Phase 2 | |
| Completed |
NCT03223428 -
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
|
||
| Active, not recruiting |
NCT05361668 -
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
|
Phase 2 | |
| Completed |
NCT01104415 -
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
|
Phase 2 | |
| Withdrawn |
NCT01172717 -
Study of Panitumumab in the Treatment of Carcinoid Syndrome
|
Phase 2 | |
| Terminated |
NCT00884715 -
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT01677910 -
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
|
Phase 3 | |
| Completed |
NCT01430871 -
Effects of Serotonin Excess on Bone in Carcinoid Syndrome
|
N/A | |
| Completed |
NCT02026063 -
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
|
Phase 3 | |
| Terminated |
NCT01018953 -
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
|
Phase 2 | |
| Terminated |
NCT04140409 -
Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
|
Phase 4 |